The epidemiology of myelodysplastic syndromes.
The incidence of the myelodysplastic syndromes (MDS) in the United States is reported as 3.4 per 100,000 people, translating to over 10,000 new diagnoses annually. This figure is considered to be an underestimate as our data capture techniques improve, and probably translates to a prevalence of approximately 60,000 people or more living with the disease. Patients are in their seventh or eighth decades at diagnosis, typically present with cytopenias, and have substantive transfusion requirements. The most common risk factors for developing MDS include advanced age, male gender, previous exposure to chemotherapy or radiation therapy, smoking, or, in rare cases, exposure to industrial chemicals.
Sekeres
Mikkael A
MA
Department of Hematologic Oncology and Blood Disorders, Cleveland Clinic Taussig Cancer Institute, 9500 Euclid Avenue, Cleveland, OH 44195, USA.
D017677:Age Distribution; D017668:Age of Onset; D000368:Aged; D000369:Aged, 80 and over; D016573:Agrochemicals / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000009:adverse effects; D004781:Environmental Exposure; D005060:Europe / Q000453:epidemiology; D005260:Female; D006801:Humans; D015994:Incidence; D007564:Japan / Q000453:epidemiology; D008297:Male; D009190:Myelodysplastic Syndromes / Q000453:epidemiology* / Q000209:etiology; D015995:Prevalence; D011878:Radiotherapy / Q000009:adverse effects; D012307:Risk Factors; D012907:Smoking / Q000009:adverse effects; D012997:Solvents / Q000009:adverse effects; D014481:United States / Q000453:epidemiology
D016573:Agrochemicals; D000970:Antineoplastic Agents; D012997:Solvents